Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI

NCT02794402 on ClinicalTrials.gov · last registry update 2022-05-18

A small phase 2 — 44 participants, against a typical 110. The sponsor logged completion for September 2016. Primary outcome, as filed: BMI SDS (Body Mass Index Standard Deviation Score). exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Uppsala University
Sponsor type: Other
Enrollment: 44
Started: 2015-09
Primary completion: 2016-09 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

BMI SDS (Body Mass Index Standard Deviation Score)

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.